Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Arrhythmias

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 34 articles:
HTML format
Text format



Single Articles


    March 2017
  1. HEALEY JS, Oldgren J
    Risk of mortality and stroke after atrial fibrillation - Authors' reply.
    Lancet. 2017;389:907.
    PubMed     Text format    


  2. HUO Z
    Risk of mortality and stroke after atrial fibrillation.
    Lancet. 2017;389:907.
    PubMed     Text format    


  3. MIHAS C, Mariolis A, Letsas KP, Kantzanou M, et al
    Risk of mortality and stroke after atrial fibrillation.
    Lancet. 2017;389:906.
    PubMed     Text format    


    October 2016
  4. HIJAZI Z, Oldgren J, Lindback J, Siegbahn A, et al
    The ABC risk score for patients with atrial fibrillation - Authors' reply.
    Lancet. 2016;388:1980-1981.
    PubMed     Text format    


  5. CHARIDIMOU A
    The ABC risk score for patients with atrial fibrillation.
    Lancet. 2016;388:1979.
    PubMed     Text format    


  6. PROVIDENCIA R, Lambiase PD
    The ABC risk score for patients with atrial fibrillation.
    Lancet. 2016;388:1979-1980.
    PubMed     Text format    


    August 2016
  7. BRIASOULIS A, Afonso L
    Do NOACs ENSURE safe cardioversion in atrial fibrillation?
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31410.
    PubMed     Text format    


  8. GOETTE A, Merino JL, Ezekowitz MD, Zamoryakhin D, et al
    Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31474.
    PubMed     Text format     Abstract available


  9. PICCINI JP, Fauchier L
    Rhythm control in atrial fibrillation.
    Lancet. 2016;388:829-840.
    PubMed     Text format     Abstract available


  10. VAN GELDER IC, Rienstra M, Crijns HJ, Olshansky B, et al
    Rate control in atrial fibrillation.
    Lancet. 2016;388:818-828.
    PubMed     Text format     Abstract available


  11. FREEDMAN B, Potpara TS, Lip GY
    Stroke prevention in atrial fibrillation.
    Lancet. 2016;388:806-817.
    PubMed     Text format     Abstract available


  12. THE LANCET
    Atrial fibrillation and stroke: unrecognised and undertreated.
    Lancet. 2016;388:731.
    PubMed     Text format    


  13. LARSEN TB, Nielsen PB
    Stroke and mortality after atrial fibrillation-a global struggle.
    Lancet. 2016 Aug 8. pii: S0140-6736(16)31274.
    PubMed     Text format    


  14. HEALEY JS, Oldgren J, Ezekowitz M, Zhu J, et al
    Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study.
    Lancet. 2016 Aug 8. pii: S0140-6736(16)30968.
    PubMed     Text format     Abstract available


    July 2016
  15. O'DONNELL MJ, Chin SL, Rangarajan S, Xavier D, et al
    Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.
    Lancet. 2016 Jul 15. pii: S0140-6736(16)30506.
    PubMed     Text format     Abstract available


    April 2016
  16. CAMPANILE A, Tavazzi G, Alam MH, Paul R, et al
    An unexpected finding in an asymptomatic patient with atrial fibrillation: cardiac angiosarcoma.
    Lancet. 2016 Apr 7. pii: S0140-6736(16)00086.
    PubMed     Text format    


  17. HIJAZI Z, Oldgren J, Lindback J, Alexander JH, et al
    The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
    Lancet. 2016 Apr 1. pii: S0140-6736(16)00741.
    PubMed     Text format     Abstract available


  18. KIRCHHOF P, Fabritz L
    Can biomarkers balance stroke and bleeding risk?
    Lancet. 2016 Apr 1. pii: S0140-6736(16)30121.
    PubMed     Text format    


    February 2016
  19. BLACHER J, Levy BI, Mourad JJ, Safar ME, et al
    From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century.
    Lancet. 2016 Feb 5. pii: S0140-6736(16)00002.
    PubMed     Text format    


    October 2015
  20. VERHEUGT FW, Granger CB
    Intracerebral haemorrhage, atrial fibrillation, and anticoagulation - Authors' reply.
    Lancet. 2015;386:1737.
    PubMed     Text format    


  21. WILSON D, Al-Shahi Salman R, Klijn CJ, Lip GY, et al
    Intracerebral haemorrhage, atrial fibrillation, and anticoagulation.
    Lancet. 2015;386:1736-7.
    PubMed     Text format    


  22. THAN M, Peacock WF
    Supraventricular tachycardia: back to basics.
    Lancet. 2015;386:1712.
    PubMed     Text format    


  23. APPELBOAM A, Reuben A, Mann C, Gagg J, et al
    Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial.
    Lancet. 2015;386:1747-53.
    PubMed     Text format     Abstract available


  24. FREEDMAN SB, Martinez C, Lowres N, Neubeck L, et al
    "Off the pulse" about incidental atrial fibrillation.
    Lancet. 2015;386:1339-40.
    PubMed     Text format    


    August 2015
  25. TOWBIN JA, Lorts A, Jefferies JL
    Left ventricular non-compaction cardiomyopathy.
    Lancet. 2015;386:813-25.
    PubMed     Text format     Abstract available


    July 2015
  26. DATINO T
    ADVICE on adenosine to improve atrial fibrillation ablation.
    Lancet. 2015 Jul 23. pii: S0140-6736(15)60241.
    PubMed     Text format    


  27. MACLE L, Khairy P, Weerasooriya R, Novak P, et al
    Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial.
    Lancet. 2015 Jul 23. pii: S0140-6736(15)60026.
    PubMed     Text format     Abstract available


    June 2015
  28. RUFF CT, Giugliano RP, Braunwald E, Morrow DA, et al
    Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Lancet. 2015;385:2288-95.
    PubMed     Text format     Abstract available


  29. WU AH
    Pharmacogenomic testing and response to warfarin.
    Lancet. 2015;385:2231-2.
    PubMed     Text format    


  30. PATEL MR, Washam JB
    Edoxaban and the need for outcomes-based NOAC dosing.
    Lancet. 2015;385:2232-3.
    PubMed     Text format    


  31. MEGA JL, Walker JR, Ruff CT, Vandell AG, et al
    Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Lancet. 2015;385:2280-7.
    PubMed     Text format     Abstract available


    May 2015
  32. SCHNABEL RB, Yin X, Gona P, Larson MG, et al
    50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study.
    Lancet. 2015 May 7. pii: S0140-6736(14)61774.
    PubMed     Text format     Abstract available


  33. POTTER BJ, Le Lorier J
    Taking the pulse of atrial fibrillation.
    Lancet. 2015 May 7. pii: S0140-6736(14)61991.
    PubMed     Text format    


    February 2015
  34. REILLY S, Liu X, Carnicer R, Rajakumar T, et al
    Evaluation of the role of miR-31-dependent reduction in dystrophin and nNOS on atrial-fibrillation-induced electrical remodelling in man.
    Lancet. 2015;385 Suppl 1:S82.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: